We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EXP:NYSEEagle Materials Inc Analysis

Data as of 2026-04-01 - not real-time

$190.96

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Eagle Materials is trading at $190.96, well below its 20‑day ($187.31), 50‑day ($209.26) and 200‑day ($219.03) moving averages, indicating a bearish price trend despite a modestly bullish MACD histogram and a neutral RSI of 46. The stock’s 30‑day volatility of 38% and beta around 1.05 suggest heightened price swings, while volume is rising, confirming active market interest. Fundamentally, the company posts solid margins (gross 28%, operating 25%) and a strong ROE of 28%, yet carries a high debt‑to‑equity ratio of 120% and a modest dividend yield of 0.53% with a low payout ratio of 7.6%.
The discounted cash‑flow model values EXP at roughly $22.80, implying the market price is overvalued by more than 700% and limiting upside to about 16% relative to the DCF estimate. Analysts are split, with a consensus “hold” rating, RBC initiating coverage with a sector‑perform stance, and JP Morgan downgrading to underweight. Given the technical bearishness, valuation disconnect, and elevated debt, the near‑term outlook is cautious, while the dividend and cash‑flow generation provide some defensive qualities for longer horizons.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below key moving averages signaling bearish momentum
  • High short‑term volatility and elevated beta
  • Significant overvaluation relative to DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong operating margins and cash‑flow generation
  • Low dividend payout supporting sustainability
  • Analyst consensus of hold and mixed coverage opinions

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Durable demand for construction materials and gypsum products
  • Consistent dividend and solid ROE
  • Potential for debt reduction improving balance‑sheet strength

Key Metrics & Analysis

Financial Health

Revenue Growth-0.40%
Profit Margin18.70%
P/E Ratio14.4
ROE28.77%
ROA10.26%
Debt/Equity120.57
P/B Ratio4.0
Op. Cash Flow$574.8M
Free Cash Flow$156.2M

Technical Analysis

TrendBearish
RSI46.2
Support$171.99
Resistance$211.81
MA 20$187.31
MA 50$209.26
MA 200$219.03
MACDBullish
VolumeIncreasing
Fear & Greed Index77.61

Valuation

Fair Value$22.80
Target Price$222.55
Upside/Downside16.54%
GradeOvervalued
TypeValue
Dividend Yield0.53%

Risk Assessment

Beta1.05
Volatility38.14%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.